Adipose-derived MSC therapy

Class

Autologous/allogeneic adipose-derived mesenchymal stem cell therapy

Adipose-derived mesenchymal stem cells (MSCs) are multipotent stromal cells isolated from fat tissue that can self-renew and secrete a wide range of signaling molecules. Rather than acting through a single molecular target, this therapy relies on the biological behavior of living cells once delivered to a site of tissue damage or chronic inflammation. The rationale rests on three overlapping properties: MSCs dampen local immune activity by shifting the balance away from pro-inflammatory signaling, they support tissue repair through paracrine secretion of growth factors and cytokines that recruit and support resident repair cells, and in some settings they can differentiate into related mesodermal lineages such as fat, cartilage, or bone. These properties make MSC therapy relevant to chronic inflammatory, fibrotic, and structural tissue conditions where ordinary healing is impaired, including fistulizing disease, degenerative joint disorders, and soft-tissue or wound defects. Products may be autologous (the patient's own cells, avoiding immune rejection but requiring individualized processing) or allogeneic (donor-derived, allowing standardized manufacturing but carrying some risk of immune clearance). Overall, this approach represents a departure from conventional single-molecule pharmacology, using a living, multifunctional cell population that responds adaptively to its local tissue environment.